Xenon’s CEO and CFO bought $1.68 million on the same day.

Xenon’s CEO and CFO purchased 45,000 shares on September 30. TradingEdgeIQ highlighted the disclosure and helped put their commitment into research context.

Anuj Saxena · Founder, TradingEdgeIQ

A CEO purchase can put a company on an investor’s radar. A CFO buying on the same day adds another detail worth following.

On September 30, 2026, Xenon Pharmaceuticals CEO Ian Mortimer and CFO Thomas Patrick Kelly purchased a combined 45,000 shares for approximately $1.68 million. Their SEC disclosures became public the following morning.

TradingEdgeIQ’s Public Filings Intelligence solution highlighted the activity with an Activity Relevance score of 82 out of 100 in its October 1 snapshot, making a substantial management commitment easier to find.

Previous in this collection: Three purchases. $1.745 million. A clearer picture at Dick’s.

Next in this collection: GameStop’s $48.5 million buying pattern went beyond Ryan Cohen.

What the filings show

Mortimer purchased 30,000 shares at a reported weighted average price of $37.38, totaling $1,121,400. Kelly purchased 15,000 shares at $37.316, totaling $559,740. The combined reported purchase value was $1,681,140.

The source records are Mortimer’s Form 4 and Kelly’s Form 4.

Both purchases followed a substantial September decline in Xenon’s share price. That gives investors a useful context for evaluating the commitments: two senior executives bought during a period when the market was reassessing the company.

The business questions behind the buying

Xenon’s September 17 company update reported an FDA application submission for azetukalner in focal seizures and a temporary pause in new patient enrollment in its psychiatry studies. Those developments make the management purchases more interesting to investigate alongside the company’s clinical milestones. Read Xenon’s update.

An investor can now approach the research with a defined question: how does the CEO’s and CFO’s commitment fit with the development program, upcoming milestones, and the company’s resources?

The purchases add evidence about management’s willingness to commit capital. Clinical progress remains something to evaluate through the company’s development disclosures.

How TradingEdgeIQ helps

Public Filings Intelligence saves users the work of finding and assembling the disclosures before they can investigate that question. The transaction amounts and dates give substance to the story; the relevance score helps users decide where to spend their research time.

The October 1 record carried Medium Evidence Confidence because the ownership comparison was incomplete. Users can still inspect the reported purchases while understanding which part of the surrounding ownership picture needs another check.

With the activity organized, an investor can compare the commitment with the clinical outlook, valuation, and their own trading criteria. That makes the next decision more informed and easier to explain.

Discover meaningful insider activity with TradingEdgeIQ’s Public Filings Intelligence solution.

Previous in this collection: Three purchases. $1.745 million. A clearer picture at Dick’s.

Next in this collection: GameStop’s $48.5 million buying pattern went beyond Ryan Cohen.

Research and analytics only. No auto-trading. No financial advice. Historical and simulated results do not guarantee future performance.